PF-ILD | ||||||||
IPF | Non-IPF | |||||||
Total (n=64) | Antifibrotic (n=42) | No-antifibrotic (n=22) | P value | Total (n=103) | Antifibrotic (n=34) | No-antifibrotic (n=69) | P value | |
Characteristics | ||||||||
Sex, male | 48 (75.0) * | 29 (69.05) | 19 (86.36) | 0.2233 | 67 (65.05) | 24 (70.59) | 43 (62.32) | 0.5112 |
Age (years) | 73.0 (68.25–77.0) | 71.5 (66.75 76.25) | 74.5 (70.75–77.25) | 0.1902 | 70.0 (62.0–74.0) | 69.5 (63.25–74) | 70 (61.0–73.5) | 0.5672 |
BMI | 23.65 (21.77–26.16) | 23.81 (21.63–26.71) | 23.27 (21.82–25.11) | 0.7132 | 22.37 (20.44–25.07) | 23.57 (20.98–26.47) | 21.93 (20.02–24.26) | 0.0198 |
COPD | 9 (14.06) | 5 (11.9) | 4 (18.18) | 0.4804 | 15 (12.62) | 7 (20.59) | 8 (11.59) | 0.2452 |
DM | 11 (17.19) | 5 (11.9) | 6 (27.27) | 0.1659 | 13 (12.62) | 3 (8.82) | 10 (14.49) | 0.5371 |
Serological examination | ||||||||
Monocyte count | 411.9 (331.8–531.8) | 402.6 (329.7–539) | 438.1 (332.3–515.1) | 0.9464 | 432.2 (329.5–555.2) | 437.7 (379.8–554.7) | 427 (302.1–556.2) | 0.387 |
LDH | 215 (192–260) | 214 (192–248) | 216 (185.3–267.5) | 0.9107 | 218 (190–251) | 213 (181.5–246.5) | 224.5 (190.8–251) | 0.528 |
KL-6 | 926.6 (681.5–1588.1) | 916.4 (740.5–1606) | 1014.5 (538.9–1549.3) | 0.8550 | 827.5 (571–1267.5) | 829 (598.6–1423.1) | 826 (513.8–1166.6) | 0.369 |
CRP | 0.16 (0.1–0.44) | 0.16 (0.1–0.32) | 0.155 (0.1–0.46) | 0.9437 | 0.16 (0.1–0.36) | 0.18 (0.1–0.35) | 0.19 (0.1–0.42) | 0.8083 |
Pulmonary function | ||||||||
FVC | 2.32 (1.90–2.85) | 2.29 (1.89–2.87) | 2.43 (1.88–2.86) | 0.9039 | 2.28 (1.78–2.84) | 2.33 (1.96–2.77) | 2.24 ( 1.73–2.86) | 0.9841 |
%FVC | 84.45 (72.45–93.63) | 86.55 (72.83–94) | 84.2 (70.33–92.83) | 0.5456 | 78.7 (65.1–90.4) | 79.3 (63.0–90.75) | 78.3 (67.2–89.3) | 0.7737 |
DLCO (n=125) | 10.36 (7.88–12.2) | 11.04 (8.41–12.74) | 8.61 (7.10–11.59) | 0.0962 | 9.89 (7.29–11.87) | 9.69 (7.26–11.76) | 10.18 (7.37–12.22) | 0.7664 |
%DLCO (n=125) | 60.42 (47.03–78.09) | 69.66 (49.05–80.97) | 51.7 (42.4–69.72) | 0.0527 | 57.8 (41.68–73.25) | 52.8 (40.03–71.75) | 61.05 (43.73–74.68) | 0.3081 |
Radiological findings | ||||||||
Honeycombing | 36 (56.25) | 22 (52.38) | 14 (63.64) | 0.4363 | 29 (28.16) | 12 (35.29) | 17 (24.64) | 0.2581 |
Traction bronchiectasis | 41 (64.06) | 27 (64.29) | 14 (63.63) | 1.000 | 60 (58.25) | 22 (64.71) | 38 (55.07) | 0.3512 |
Immunosuppressive agents | ||||||||
Glucocorticoids (PSL<10 mg/day) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1.000 | 12 (11.65) | 3 (8.82) | 9 (13.04) | 0.7464 |
Glucocorticoids (PSL≥10 mg/day) | 7 (10.94) | 4 (9.52) | 3 (13.64) | 0.6837 | 16 (15.53) | 5 (14.71) | 11 (15.94) | 1.000 |
Immunosuppressant | 2 (3.13) | 1 (2.38) | 1 (4.55) | 1.000 | 14 (13.59) | 6 (17.65) | 8 (11.59) | 0.5417 |
*Data are shown as n (%) or median (IQR).
COPD; chronic obstructive lung pulmonary disease; BMI, body mass index; CRP, C-reactive protein; DLCO, diffusing capacity for carbon monoxide; DM, diabetes mellitus; FVC, forced vital capacity; IPF, idiopathic pulmonary fibrosis; KL-6, sialylated carbohydrate antigen Krebs von den Lungen-6; LDH, lactate dehydrogenase; PF-ILD, progressive fibrosing interstitial lung disease; PSL, prednisolone.